Hongze Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hongze Chen has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Bei Sun
Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
5 shared publications Wenbo Yang
Department of Hepatobiliary and Pancreas Surgery, The First Affiliated Hospital of Harbin Medical University
4 shared publicationsXuewei Bai
Department of Pancreatic and Biliary Surgery, First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin, 150001, Heilongjiang Province, China
4 shared publicationsChundong Cheng
Department of Hepatobiliary and Pancreas Surgery, Qunli District, The First Affiliated Hospital of Harbin Medical University, Harbin, China
3 shared publicationsGuanqun Li
Department of Pancreatic and Biliary Surgery The First Affiliated Hospital of Harbin Medical University Key Laboratory of Hepatosplenic Surgery Ministry of Education The First Affiliated Hospital of Harbin Medical University Harbin Heilongjiang 150000 China
3 shared publications- Xuewei Bai
The Pancreatic Disease Diagnosis and Treatment Center, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
3 shared publications
Latest Publications
- Open Access
- 24 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13
The role of epigenetic modifications in cancer-associated fibroblasts
Cancer-associated fibroblasts (CAFs) constitute a heterogeneous population of stromal cells whose tumor-modulating activities are highly context-dependent. Unlike cancer cells, CAFs rarely harbor stable genetic mutations; instead, their phenotypic plasticity is largely driven by reversible epigenetic reprogramming. Within the tumor microenvironment (TME), CAFs function as key regulators by secreting extracellular matrix (ECM) components, paracrine growth factors, cytokines, and metabolic intermediates that collectively promote tumor growth, invasion, and therapeutic resistance. Recent advances in cancer biology have shifted attention from solely cataloging coding-sequence mutations toward understanding the epigenetic mechanisms that shape CAF identity and function. Major epigenetic regulatory mechanisms include DNA methylation, histone modifications, and RNA modifications, which dynamically regulate chromatin structure and gene expression without altering the underlying DNA sequence. Emerging evidence indicates that the activation and functional heterogeneity of CAFs are predominantly governed by these epigenetic alterations rather than by permanent genetic changes. Epigenetic reprogramming enables CAFs to acquire diverse tumor-promoting properties, including remodeling of the extracellular matrix, modulation of intercellular signaling pathways, and secretion of cytokines that influence gene expression in neighboring cancer and immune cells. These processes ultimately contribute to tumor initiation, progression, metastasis, and resistance to therapy. This review summarizes recent advances in understanding how epigenetic modifications regulate CAF activation and function within the tumor microenvironment. In addition, we discuss the potential of targeting CAF-associated epigenetic pathways as a promising therapeutic strategy for cancer treatment.
- 24 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13
Open AccessThe role of epigenetic modifications in cancer-associated fibroblasts
Cancer-associated fibroblasts (CAFs) constitute a heterogeneous population of stromal cells whose tumor-modulating activities are highly context-dependent. Unlike cancer cells, CAFs rarely harbor stable genetic mutations; instead, their phenotypic plasticity is largely driven by reversible epigenetic reprogramming. Within the tumor microenvironment (TME), CAFs function as key regulators by secreting extracellular matrix (ECM) components, paracrine growth factors, cytokines, and metabolic intermediates that collectively promote tumor growth, invasion, and therapeutic resistance. Recent advances in cancer biology have shifted attention from solely cataloging coding-sequence mutations toward understanding the epigenetic mechanisms that shape CAF identity and function. Major epigenetic regulatory mechanisms include DNA methylation, histone modifications, and RNA modifications, which dynamically regulate chromatin structure and gene expression without altering the underlying DNA sequence. Emerging evidence indicates that the activation and functional heterogeneity of CAFs are predominantly governed by these epigenetic alterations rather than by permanent genetic changes. Epigenetic reprogramming enables CAFs to acquire diverse tumor-promoting properties, including remodeling of the extracellular matrix, modulation of intercellular signaling pathways, and secretion of cytokines that influence gene expression in neighboring cancer and immune cells. These processes ultimately contribute to tumor initiation, progression, metastasis, and resistance to therapy. This review summarizes recent advances in understanding how epigenetic modifications regulate CAF activation and function within the tumor microenvironment. In addition, we discuss the potential of targeting CAF-associated epigenetic pathways as a promising therapeutic strategy for cancer treatment.
- Open Access
RBX1+ CAFs Drives Pancreatic Ductal Adenocarcinoma Progression Through Tenascin C Overexpression
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense desmoplastic stroma that actively drives malignant progression. However, the specific contributions of E3 ubiquitin ligases within the cancer-associated fibroblast (CAFs) compartment to the PDAC landscape remain largely elusive. Methods: Pancreatic tissue samples were collected from the First Affiliated Hospital of Harbin Medical University. Gene expression was analyzed by RT-PCR, and single-cell RNA sequencing (scRNA-seq) data were integrated for cell subtype identification. Kaplan-Meier survival analysis assessed gene expression and survival. Pseudotime analysis and CellChat evaluated fibroblast transitions and intercellular communication. Cell lines were transfected with RBX1 siRNAs, and protein levels were measured by Western blotting. Proliferation was assessed using colony formation and EdU staining. Statistical analyses were performed using R (v4.4) and GraphPad Prism 8.0. Results: Thirteen E3 ubiquitin ligases were significantly upregulated in PDAC and correlated with unfavorable clinical outcomes. Among these, RBX1 was identified as a candidate preferentially expressed in CAF populations and strongly associated with poor prognosis. Single-cell transcriptomic profiling and pseudotime analysis further revealed that RBX1-positive CAFs were predominantly involved in extracellular matrix remodeling and pro-tumorigenic pathways. Functional assays demonstrated that silencing RBX1 markedly inhibited PAAD cell proliferation and tumor growth both in vitro and in xenograft models. Mechanistically, RBX1 was found to upregulate Tenascin C (TNC) expression, while ectopic overexpression of TNC partially rescued the growth suppression induced by RBX1 knockdown. Conclusions: Our findings suggest that RBX1 facilitates PDAC progression through a CAF-related mechanism and TNC regulation, positioning RBX1 as a potential therapeutic target for PDAC intervention.
Open AccessRBX1+ CAFs Drives Pancreatic Ductal Adenocarcinoma Progression Through Tenascin C Overexpression
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense desmoplastic stroma that actively drives malignant progression. However, the specific contributions of E3 ubiquitin ligases within the cancer-associated fibroblast (CAFs) compartment to the PDAC landscape remain largely elusive. Methods: Pancreatic tissue samples were collected from the First Affiliated Hospital of Harbin Medical University. Gene expression was analyzed by RT-PCR, and single-cell RNA sequencing (scRNA-seq) data were integrated for cell subtype identification. Kaplan-Meier survival analysis assessed gene expression and survival. Pseudotime analysis and CellChat evaluated fibroblast transitions and intercellular communication. Cell lines were transfected with RBX1 siRNAs, and protein levels were measured by Western blotting. Proliferation was assessed using colony formation and EdU staining. Statistical analyses were performed using R (v4.4) and GraphPad Prism 8.0. Results: Thirteen E3 ubiquitin ligases were significantly upregulated in PDAC and correlated with unfavorable clinical outcomes. Among these, RBX1 was identified as a candidate preferentially expressed in CAF populations and strongly associated with poor prognosis. Single-cell transcriptomic profiling and pseudotime analysis further revealed that RBX1-positive CAFs were predominantly involved in extracellular matrix remodeling and pro-tumorigenic pathways. Functional assays demonstrated that silencing RBX1 markedly inhibited PAAD cell proliferation and tumor growth both in vitro and in xenograft models. Mechanistically, RBX1 was found to upregulate Tenascin C (TNC) expression, while ectopic overexpression of TNC partially rescued the growth suppression induced by RBX1 knockdown. Conclusions: Our findings suggest that RBX1 facilitates PDAC progression through a CAF-related mechanism and TNC regulation, positioning RBX1 as a potential therapeutic target for PDAC intervention.
- Open Access
- 25 November 2025
- Published by Springer Nature in Oncogene
- Vol. 45 (1) , 26-41
RNF187 neddylation in pancreatic cancer activates malignancy via IQGAP1-dependent actin cytoskeleton rearrangement
Neddylation, a post-translational modification process involving three enzymatic steps, is crucial in regulating various cancers. However, its specific mechanisms in pancreatic cancer (PC) remain largely unexplored. This study focused on screening neddylation-related molecules in PC and identified RNF187 as a key player, demonstrating its overexpression in PC and its ability to enhance cell proliferation and invasion both in vitro and in vivo. Notably, NEDD8 could bind to RNF187, preventing its degradation via K48-linked ubiquitination. This interaction stabilized RNF187, leading to increased protein levels and subsequent stimulation of PC cell proliferation and invasion. However, this mechanism alone did not fully account for how RNF187 could exacerbate PC malignancy. Further research revealed that RNF187 upregulated IQGAP1 protein levels through modulation of K48- and K63-linked ubiquitination. This post-translational modification triggered the rearrangement of the actin cytoskeleton in PC cells by altering the transcriptional levels of MYH9, thereby promoting PC malignancy. Overall, our findings demonstrate that neddylation of RNF187 enhances PC malignancy through the IQGAP1/MYH9 axis, suggesting a new therapeutic target for PC.
- 25 November 2025
- Published by Springer Nature in Oncogene
- Vol. 45 (1) , 26-41
Open AccessRNF187 neddylation in pancreatic cancer activates malignancy via IQGAP1-dependent actin cytoskeleton rearrangement
Neddylation, a post-translational modification process involving three enzymatic steps, is crucial in regulating various cancers. However, its specific mechanisms in pancreatic cancer (PC) remain largely unexplored. This study focused on screening neddylation-related molecules in PC and identified RNF187 as a key player, demonstrating its overexpression in PC and its ability to enhance cell proliferation and invasion both in vitro and in vivo. Notably, NEDD8 could bind to RNF187, preventing its degradation via K48-linked ubiquitination. This interaction stabilized RNF187, leading to increased protein levels and subsequent stimulation of PC cell proliferation and invasion. However, this mechanism alone did not fully account for how RNF187 could exacerbate PC malignancy. Further research revealed that RNF187 upregulated IQGAP1 protein levels through modulation of K48- and K63-linked ubiquitination. This post-translational modification triggered the rearrangement of the actin cytoskeleton in PC cells by altering the transcriptional levels of MYH9, thereby promoting PC malignancy. Overall, our findings demonstrate that neddylation of RNF187 enhances PC malignancy through the IQGAP1/MYH9 axis, suggesting a new therapeutic target for PC.
- Open Access
- 31 March 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (5) , 1101-1117
Liver TET1 promotes metabolic dysfunction-associated steatotic liver disease
Global hepatic DNA methylation change has been linked to human patients with metabolic dysfunction-associated steatotic liver disease (MASLD). DNA demethylation is regulated by the TET family proteins, whose enzymatic activities require 2-oxoglutarate (2-OG) and iron that both are elevated in human MASLD patients. We aimed to investigate liver TET1 in MASLD progression. Depleting TET1 using two different strategies substantially alleviated MASLD progression. Knockout (KO) of TET1 slightly improved diet induced obesity and glucose homeostasis. Intriguingly, hepatic cholesterols, triglycerides, and CD36 were significantly decreased upon TET1 depletion. Consistently, liver specific TET1 KO led to improvement of MASLD progression. Mechanistically, TET1 promoted CD36 expression through transcriptional upregulation via DNA demethylation control. Overexpression of CD36 reversed the impacts of TET1 downregulation on fatty acid uptake in hepatocytes. More importantly, targeting TET1 with a small molecule inhibitor significantly suppressed MASLD progression. Conclusively, liver TET1 plays a deleterious role in MASLD, suggesting the potential of targeting TET1 in hepatocytes to suppress MASLD.
- 31 March 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (5) , 1101-1117
Open AccessLiver TET1 promotes metabolic dysfunction-associated steatotic liver disease
Global hepatic DNA methylation change has been linked to human patients with metabolic dysfunction-associated steatotic liver disease (MASLD). DNA demethylation is regulated by the TET family proteins, whose enzymatic activities require 2-oxoglutarate (2-OG) and iron that both are elevated in human MASLD patients. We aimed to investigate liver TET1 in MASLD progression. Depleting TET1 using two different strategies substantially alleviated MASLD progression. Knockout (KO) of TET1 slightly improved diet induced obesity and glucose homeostasis. Intriguingly, hepatic cholesterols, triglycerides, and CD36 were significantly decreased upon TET1 depletion. Consistently, liver specific TET1 KO led to improvement of MASLD progression. Mechanistically, TET1 promoted CD36 expression through transcriptional upregulation via DNA demethylation control. Overexpression of CD36 reversed the impacts of TET1 downregulation on fatty acid uptake in hepatocytes. More importantly, targeting TET1 with a small molecule inhibitor significantly suppressed MASLD progression. Conclusively, liver TET1 plays a deleterious role in MASLD, suggesting the potential of targeting TET1 in hepatocytes to suppress MASLD.
- 15 November 2023
- Published by Elsevier in Cancer Letters
- Vol. 580, 216493
Elevated 2-oxoglutarate antagonizes DNA damage responses in cholangiocarcinoma chemotherapy through regulating aspartate beta-hydroxylase
- 15 November 2023
- Published by Elsevier in Cancer Letters
- Vol. 580, 216493
Elevated 2-oxoglutarate antagonizes DNA damage responses in cholangiocarcinoma chemotherapy through regulating aspartate beta-hydroxylase
- Open Access
- 2 February 2023
- Published by Wiley in Advanced Science
- Vol. 10 (10)
Tumor Cell Derived Lnc‐FSD2‐31:1 Contributes to Cancer‐Associated Fibroblasts Activation in Pancreatic Ductal Adenocarcinoma Progression through Extracellular Vesicles Cargo MiR‐4736
Pancreatic ductal adenocarcinoma (PDAC) presents with high mortality and short overall survival. Cancer‐associated fibroblasts (CAFs) act as refuge for cancer cells in PDAC. Mechanisms of intracelluar communication between CAFs and cancer cells need to be explored. Long noncoding RNAs (lncRNAs) are involved in the modulation of oncogenesis and tumor progression of PDAC; however, specific lncRNAs and their mechanism of action have not been clarified clearly in tumoral microenvironment. This work aims to identify novel lncRNAs involved in cellular interaction between cancer cells and CAFs in PDAC. To this end, differentially expressed lncRNAs between long‐term and short‐term survival PDAC patients are screened. Lnc‐FSD2‐31:1 is found to be significantly increased in long‐term survival patients. This work then discovers that tumor‐derived lnc‐FSD2‐31:1 restrains CAFs activation via miR‐4736 transported by extracellular vesicles (EVs) in vitro and in vivo. Mechanistically, EVs‐derived miR‐4736 suppresses autophagy and contributes to CAFs activation by targeting ATG7. Furthermore, blocking miR‐4736 suppresses tumor growth in genetically engineered KPC (LSL‐KrasG12D/+, LSL‐Trp53R172H/+, and Pdx‐1‐Cre) mouse model of PDAC. This study demonstrates that intratumoral lnc‐FSD2‐31:1 modulates autophagy in CAFs resulting in their activation through EVs‐derived miR‐4736. Targeting miR‐4736 may be a potential biomarker and therapeutic target for PDAC.
- 2 February 2023
- Published by Wiley in Advanced Science
- Vol. 10 (10)
Open AccessTumor Cell Derived Lnc‐FSD2‐31:1 Contributes to Cancer‐Associated Fibroblasts Activation in Pancreatic Ductal Adenocarcinoma Progression through Extracellular Vesicles Cargo MiR‐4736
Pancreatic ductal adenocarcinoma (PDAC) presents with high mortality and short overall survival. Cancer‐associated fibroblasts (CAFs) act as refuge for cancer cells in PDAC. Mechanisms of intracelluar communication between CAFs and cancer cells need to be explored. Long noncoding RNAs (lncRNAs) are involved in the modulation of oncogenesis and tumor progression of PDAC; however, specific lncRNAs and their mechanism of action have not been clarified clearly in tumoral microenvironment. This work aims to identify novel lncRNAs involved in cellular interaction between cancer cells and CAFs in PDAC. To this end, differentially expressed lncRNAs between long‐term and short‐term survival PDAC patients are screened. Lnc‐FSD2‐31:1 is found to be significantly increased in long‐term survival patients. This work then discovers that tumor‐derived lnc‐FSD2‐31:1 restrains CAFs activation via miR‐4736 transported by extracellular vesicles (EVs) in vitro and in vivo. Mechanistically, EVs‐derived miR‐4736 suppresses autophagy and contributes to CAFs activation by targeting ATG7. Furthermore, blocking miR‐4736 suppresses tumor growth in genetically engineered KPC (LSL‐KrasG12D/+, LSL‐Trp53R172H/+, and Pdx‐1‐Cre) mouse model of PDAC. This study demonstrates that intratumoral lnc‐FSD2‐31:1 modulates autophagy in CAFs resulting in their activation through EVs‐derived miR‐4736. Targeting miR‐4736 may be a potential biomarker and therapeutic target for PDAC.
- Open Access
- 21 February 2022
- Published by Springer Nature in Research Square
Lnc-FSD2-31:1 in Pancreatic ductal adenocarcinoma promotes ATG7-mediated proliferation and fibrosis of cancer associated fibroblasts via exosome miR-4736
Background Long non-coding RNA (lncRNA) is closely related to the occurrence of Pancreatic ductal adenocarcinoma (PDAC). Intercellular interactions between cancer associated fibroblasts (CAFs) and cancer cells influence malignant proliferation and chemotherapy resistance of PDAC in a variety of ways. We performed the global expression profiles of lncRNA between longevity and short survival PDAC patients’ pancreatic tissues, to identify molecular mechanism of PDAC. Method Tissue microarray (TMA) was used to explore survival related lncRNA in PDAC. The localization of lncRNA was conform by RNA fluorescence in-situ hybridization (FISH) analysis. Functional assays were introduced to demonstrate the anti-tumor effects of lncRNA in vitro and in vivo. Exosomes and primary CAFs were isolated from PDAC cell lines and patient tissues. Bioinformatics and 3D co-culture model were used to find the downstream targets. KPC transgenic mouse model and human cytokine array were also applied to detect the mechanism of PDAC. Results We found that lnc-FSD2-31:1 was elevated significantly in longevity survival patients. Lnc-FSD2-31:1 suppressed PDAC proliferation, invasion, and metastasis in vitro and in vivo. Lnc-FSD2-31:1 also act as a competing endogenous RNA (ceRNA) to inhibit miR-4736 expression in PDAC cells. Exosome miR-4736 secreted by PDAC was transported to CAFs. We found miR-4736 inhibited the proliferation, autophagy and promoted the fibrosis of CAFs by binding to the 3’-untranslated region(3’-UTR) of ATG7. Under the stimulatory of miR-4736, CAFs particularly secreted IL-32α, IL-1β, IL-1ra, G-CSF, IL-2, IL-4. Furthermore, miR-4736 antagomir intraperitoneally injected can suppressed tumor growth in KPC mice. Exosome miR-4736 of plasma might be a biomarker of PDAC. Conclusions Lnc-FSD2-31:1 suppress PDAC progression and act as a competing endogenous RNA (ceRNA) to inhibit miR-4736 expression in PDAC cells. Exosome miR-4736 released by PDAC inhibit autophagy and promote fibrosis of CAFs via targeting ATG7. miR-4736 might be a promising biomarker and treatment target of PDAC.
- 21 February 2022
- Published by Springer Nature in Research Square
Open AccessLnc-FSD2-31:1 in Pancreatic ductal adenocarcinoma promotes ATG7-mediated proliferation and fibrosis of cancer associated fibroblasts via exosome miR-4736
Background Long non-coding RNA (lncRNA) is closely related to the occurrence of Pancreatic ductal adenocarcinoma (PDAC). Intercellular interactions between cancer associated fibroblasts (CAFs) and cancer cells influence malignant proliferation and chemotherapy resistance of PDAC in a variety of ways. We performed the global expression profiles of lncRNA between longevity and short survival PDAC patients’ pancreatic tissues, to identify molecular mechanism of PDAC. Method Tissue microarray (TMA) was used to explore survival related lncRNA in PDAC. The localization of lncRNA was conform by RNA fluorescence in-situ hybridization (FISH) analysis. Functional assays were introduced to demonstrate the anti-tumor effects of lncRNA in vitro and in vivo. Exosomes and primary CAFs were isolated from PDAC cell lines and patient tissues. Bioinformatics and 3D co-culture model were used to find the downstream targets. KPC transgenic mouse model and human cytokine array were also applied to detect the mechanism of PDAC. Results We found that lnc-FSD2-31:1 was elevated significantly in longevity survival patients. Lnc-FSD2-31:1 suppressed PDAC proliferation, invasion, and metastasis in vitro and in vivo. Lnc-FSD2-31:1 also act as a competing endogenous RNA (ceRNA) to inhibit miR-4736 expression in PDAC cells. Exosome miR-4736 secreted by PDAC was transported to CAFs. We found miR-4736 inhibited the proliferation, autophagy and promoted the fibrosis of CAFs by binding to the 3’-untranslated region(3’-UTR) of ATG7. Under the stimulatory of miR-4736, CAFs particularly secreted IL-32α, IL-1β, IL-1ra, G-CSF, IL-2, IL-4. Furthermore, miR-4736 antagomir intraperitoneally injected can suppressed tumor growth in KPC mice. Exosome miR-4736 of plasma might be a biomarker of PDAC. Conclusions Lnc-FSD2-31:1 suppress PDAC progression and act as a competing endogenous RNA (ceRNA) to inhibit miR-4736 expression in PDAC cells. Exosome miR-4736 released by PDAC inhibit autophagy and promote fibrosis of CAFs via targeting ATG7. miR-4736 might be a promising biomarker and treatment target of PDAC.
- Open Access
- 25 October 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (11) , 1-11
Lnc-PFAR facilitates autophagy and exacerbates pancreatic fibrosis by reducing pre-miR-141 maturation in chronic pancreatitis
Chronic pancreatitis (CP) is described as progressive inflammatory fibrosis of pancreas, accompanied with irreversible impaired endocrine and exocrine insufficiency. Pancreatic stellate cells (PSCs) are widely distributed in the stroma of the pancreas and PSCs activation has been shown as one of the leading causes for pancreatic fibrosis. Our previous study has revealed that autophagy is dramatically activated in CP tissues, which facilitates PSCs activation and pancreatic fibrosis. Long non-coding RNAs (LncRNAs) have been recognized as crucial regulators for fibrosis-related diseases. LncRNAs interact with RNA binding protein or construct competitive endogenous RNA (ceRNA) hypothesis which elicited the fibrotic processes. Until now, the effects of lncRNAs on PSCs activation and pancreatic fibrosis have not been clearly explored. In this study, a novel lncRNA named Lnc-PFAR was found highly expressed in mouse and human CP tissues. Our data revealed that Lnc-PFAR facilitates PSCs activation and pancreatic fibrosis via RB1CC1-induced autophagy. Lnc-PFAR reduces miR-141 expression by suppressing pre-miR-141 maturation, which eventually upregulates the RB1CC1 and fibrosis-related indicators expression. Meanwhile, Lnc-PFAR enhanced PSCs activation and pancreatic fibrosis through trigging autophagy. Our study interrogates a novel lncRNA-induced mechanism in promoting the development of pancreatic fibrosis, and Lnc-PFAR is suggested to be a prospective therapeutic target in clinical scenarios.
- 25 October 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (11) , 1-11
Open AccessLnc-PFAR facilitates autophagy and exacerbates pancreatic fibrosis by reducing pre-miR-141 maturation in chronic pancreatitis
Chronic pancreatitis (CP) is described as progressive inflammatory fibrosis of pancreas, accompanied with irreversible impaired endocrine and exocrine insufficiency. Pancreatic stellate cells (PSCs) are widely distributed in the stroma of the pancreas and PSCs activation has been shown as one of the leading causes for pancreatic fibrosis. Our previous study has revealed that autophagy is dramatically activated in CP tissues, which facilitates PSCs activation and pancreatic fibrosis. Long non-coding RNAs (LncRNAs) have been recognized as crucial regulators for fibrosis-related diseases. LncRNAs interact with RNA binding protein or construct competitive endogenous RNA (ceRNA) hypothesis which elicited the fibrotic processes. Until now, the effects of lncRNAs on PSCs activation and pancreatic fibrosis have not been clearly explored. In this study, a novel lncRNA named Lnc-PFAR was found highly expressed in mouse and human CP tissues. Our data revealed that Lnc-PFAR facilitates PSCs activation and pancreatic fibrosis via RB1CC1-induced autophagy. Lnc-PFAR reduces miR-141 expression by suppressing pre-miR-141 maturation, which eventually upregulates the RB1CC1 and fibrosis-related indicators expression. Meanwhile, Lnc-PFAR enhanced PSCs activation and pancreatic fibrosis through trigging autophagy. Our study interrogates a novel lncRNA-induced mechanism in promoting the development of pancreatic fibrosis, and Lnc-PFAR is suggested to be a prospective therapeutic target in clinical scenarios.
- Open Access
- 9 July 2019
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-18
UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1
Background: Ubiquitin-like protein 4A (UBL4A) plays a significant role in protein metabolism and the maintenance of cellular homeostasis. In cancer, UBL4A represses tumorigenesis and is involved in various signaling pathways. Pancreatic ductal adenocarcinoma (PDAC) is still a major cause of cancer-related death and the underlying molecular mechanism of UBL4A and PDAC remains unknown. Methods: First, the prognostic role of UBL4A and its expression in human PDAC patients and in pancreatic cancer cell lines were detected by survival analysis and qRT-PCR, western blotting, and immunohistochemistry. Next, the effects of UBL4A on proliferation and metastasis in pancreatic cancer were evaluated by functional assays in vitro and in vivo. In addition, chloroquine was introduced to determine the role of autophagy in UBL4A-related tumor proliferation and metastasis. Ultimately, coimmunoprecipitation was used to confirm the interaction between UBL4A and lysosome associated membrane protein-1 (LAMP1), and western blotting was performed to explore the UBL4A mechanism. Results: We found that UBL4A was decreased in PDAC and that high levels of UBL4A correlated with a favorable prognosis. We observed that UBL4A inhibited tumor proliferation and metastasis through suppression of autophagy, a critical intracellular catabolic process that reportedly protects cells from nutrient starvation and other stress conditions. UBL4A caused impaired autophagic degradation in vitro, a crucial process in autophagy, by disturbing the function of lysosomes and contributing to autophagosome accumulation. We found a positive correlation between UBL4A and LAMP1. Furthermore, UBL4A caused lysosomal dysfunction by directly interacting with LAMP1, and LAMP1 overexpression reversed the antitumor effects of UBL4A in pancreatic cancer. In addition, we demonstrated that UBL4A suppressed tumor growth and metastasis in a pancreatic orthotopic tumor model. Conclusions: These findings suggest that UBL4A exerts an antitumor effect on autophagy-related proliferation and metastasis in PDAC by directly targeting LAMP1. Herein, we describe a novel mechanism of UBL4A that suppresses the progression of pancreatic cancer. UBL4A might be a promising target for the treatment and prognostication of PDAC.
- 9 July 2019
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-18
Open AccessUBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1
Background: Ubiquitin-like protein 4A (UBL4A) plays a significant role in protein metabolism and the maintenance of cellular homeostasis. In cancer, UBL4A represses tumorigenesis and is involved in various signaling pathways. Pancreatic ductal adenocarcinoma (PDAC) is still a major cause of cancer-related death and the underlying molecular mechanism of UBL4A and PDAC remains unknown. Methods: First, the prognostic role of UBL4A and its expression in human PDAC patients and in pancreatic cancer cell lines were detected by survival analysis and qRT-PCR, western blotting, and immunohistochemistry. Next, the effects of UBL4A on proliferation and metastasis in pancreatic cancer were evaluated by functional assays in vitro and in vivo. In addition, chloroquine was introduced to determine the role of autophagy in UBL4A-related tumor proliferation and metastasis. Ultimately, coimmunoprecipitation was used to confirm the interaction between UBL4A and lysosome associated membrane protein-1 (LAMP1), and western blotting was performed to explore the UBL4A mechanism. Results: We found that UBL4A was decreased in PDAC and that high levels of UBL4A correlated with a favorable prognosis. We observed that UBL4A inhibited tumor proliferation and metastasis through suppression of autophagy, a critical intracellular catabolic process that reportedly protects cells from nutrient starvation and other stress conditions. UBL4A caused impaired autophagic degradation in vitro, a crucial process in autophagy, by disturbing the function of lysosomes and contributing to autophagosome accumulation. We found a positive correlation between UBL4A and LAMP1. Furthermore, UBL4A caused lysosomal dysfunction by directly interacting with LAMP1, and LAMP1 overexpression reversed the antitumor effects of UBL4A in pancreatic cancer. In addition, we demonstrated that UBL4A suppressed tumor growth and metastasis in a pancreatic orthotopic tumor model. Conclusions: These findings suggest that UBL4A exerts an antitumor effect on autophagy-related proliferation and metastasis in PDAC by directly targeting LAMP1. Herein, we describe a novel mechanism of UBL4A that suppresses the progression of pancreatic cancer. UBL4A might be a promising target for the treatment and prognostication of PDAC.
- Open Access
- 30 September 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (44) , 71773-71781
Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer
Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer
- 30 September 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (44) , 71773-71781
Open AccessPlasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer
Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer